Stock Ratings / Health Care / ACET / forecast

IBO (34) IXHL (39) FLNA (47) LITS (42) ⌘ Pro Terminal →

Adicet Bio Inc. (ACET) 12-Month Stock Forecast & Price Target Cone

Q: Is ACET stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Adicet Bio Inc. (NASDAQ: ACET) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.58 (-6.04% 1D, market cap $33.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACET ranks #794 in composite RQD confidence.

Q: How does ACET compare to IBO and IXHL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACET carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IBO (Impact BioMedical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -27.5%, cap $33.1M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, ACET leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for ACET?

Per ACET's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001720580), Adicet Bio Inc. generated $0 in revenue, -$116.8M in net income, and -$97.0M in free cash flow against $192.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is ACET trading relative to its 50-day, 200-day, and 52-week technical levels?

ACET last traded at $3.58 (-6.04% on volume of 176,220 shares), positioning the stock -49.93% below its 50-day simple moving average ($7.15) and -53.45% below its 200-day simple moving average ($7.69). Across its 52-week range of $3.32 to $12.32, ACET sits at the 2.9% percentile with a 14-day RSI of 18.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.13 to $4.03).

Q: What is ACET's 12-month stock price target?

Adicet Bio Inc. (ACET) carries a 12-month consensus base price target of $3.23 (-9.8% from $3.58), with a bull-case target of $12.94 and a bear-case floor of $2.52.

Q: Is ACET stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ACET D- (Sell — SELL) with an RQD Confidence score of 36/100.

$3.58 -6.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.53

Adicet Bio Inc. (ACET) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $33.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.53 (-1.28%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACET)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY ACET SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 18.5 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.61-18.5% Next Q

Q2 (-2Q)

Grade D$4.57-12.7% Next Q

Q3 (-1Q)

Grade E$3.99-10.3% Next Q

Current

Grade D-$3.58-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACET Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACET currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.15) and Max Pain ($3.76) forces dealer call-delta covering toward $12.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACET• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACET Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ACET Position Size: $10,000

Shares at $3.58: 2793.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.52

$7,039

$-2,961 (-29.6%)

12M Consensus BaseTarget $3.23

$9,022

$-978 (-9.8%)

12M Bull Case BreakoutTarget $12.94

$36,145

+$26,145 (+261.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$3	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$12	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACET)

✓Walkthrough of ACET's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACET // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.58%▼ SUPPORT BREAKDOWN

2026-10-30O $3.68H $3.74L $3.32C $3.58VOL 242.5K

RES: $10.25SUP: $7.79SMA50: $7.15SMA200: $7.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACET Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACET Butterfly Map → + Track ACET →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ACET today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACET. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACET today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACET)

Health Care Rank #794 of 1016 ⚔️ IBO vs ACET Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACET vs. IBO, IXHL, FLNA, LITS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Adicet Bio Inc. (ACET) ranks #794 by composite RQD confidence (36/100, grade D-) and #791 by equity capitalization ($33.5M). Within this direct 5-issuer industry benchmark cohort, ACET leads on earnings valuation at N/A trailing P/E, while LITS leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. FLNA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ACET at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACET ACTIVE Adicet Bio Inc.	D-	36/100	—	—	-35.0%	-6.04%	$33.5M	Benchmark Subject
IBO Impact BioMedical Inc.	E	34/100	—	-30.0%	-27.5%	-3.00%	$33.1M	/ibo-vs-acet →
IXHL Incannex Healthcare Inc.	D-	39/100	—	—	-35.0%	-4.80%	$32.4M	/ixhl-vs-acet →
FLNA Filana Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.12%	$31.8M	/flna-vs-acet →
LITS Lite Strategy Inc.	D-	42/100	—	—	-18.9%	-4.88%	$35.6M	/lits-vs-acet →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001720580

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Adicet Bio Inc. (ACET) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$116.8M, operating cash flow of -$95.2M, and free cash flow of -$97.0M (-3.7% YoY). On the balance sheet, ACET closed FY2025 with $192.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$116.8M	-$95.2M	-$97.0M	$192.4M	—
FY2024 (FY)	2024-12-31	$0	-$117.1M	-$92.4M	-$93.5M	$220.2M	—
FY2023 (FY)	2023-12-31	$0	-$142.7M	-$93.7M	-$93.7M	—	—

3. ACET Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACET stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Adicet Bio Inc. (NASDAQ: ACET) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.58 (-6.04% 1D, market cap $33.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ACET ranks #794 in composite RQD confidence.

How does ACET compare to IBO and IXHL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACET carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IBO (Impact BioMedical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -27.5%, cap $33.1M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, ACET leads on earnings multiple (N/A) while LITS leads on capital efficiency (-18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACET?

Per ACET's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001720580), Adicet Bio Inc. generated $0 in revenue, -$116.8M in net income, and -$97.0M in free cash flow against $192.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACET trading relative to its 50-day, 200-day, and 52-week technical levels?

ACET last traded at $3.58 (-6.04% on volume of 176,220 shares), positioning the stock -49.93% below its 50-day simple moving average ($7.15) and -53.45% below its 200-day simple moving average ($7.69). Across its 52-week range of $3.32 to $12.32, ACET sits at the 2.9% percentile with a 14-day RSI of 18.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.13 to $4.03).

ACET Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ACET's 12-month stock price target?

Adicet Bio Inc. (ACET) carries a 12-month consensus base price target of $3.23 (-9.8% from $3.58), with a bull-case target of $12.94 and a bear-case floor of $2.52.

Is ACET stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ACET D- (Sell — SELL) with an RQD Confidence score of 36/100.

Direct Sub-Reports: ACET RQD Cockpit ACET 12M Forecast ACET Earnings & Move ACET Dividends & DRIP ACET Insiders & 13F ACET Whale Options ACET Profit Sankey ACET News & Why